Sharon Schwartz
Pediatrics · West Orange, NJNPI 1932224649
Payments from drug & device makers
Across 134 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$408
- AbbVie$204
- Jazz Pharmaceuticals Inc.$161
- Vertex$140
- Baxter Healthcare$120
- Regeneron Healthcare Solutions, Inc.$115
- plus $1K from 32 others
What the payments were for
- Food & beverage$2,14496%
- Education$904%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 26 | $408 |
| AbbVie | 13 | $204 |
| Jazz Pharmaceuticals Inc. | 6 | $161 |
| Vertex | 9 | $140 |
| Baxter Healthcare | 6 | $120 |
| Regeneron Healthcare Solutions, Inc. | 7 | $115 |
| GSK | 7 | $104 |
| Dexcom, Inc. | 6 | $97 |
| Harmony Biosciences LLC | 5 | $82 |
| Amgen | 5 | $80 |
| Biomarin Pharmaceutical Inc. | 4 | $60 |
| Viatris Specialty LLC | 1 | $59 |
| Genentech USA, Inc. | 3 | $48 |
| Electromed, Inc. | 2 | $39 |
| Gilead | 3 | $38 |
| Chiesi USA, Inc. | 2 | $36 |
| Tolmar, Inc. | 2 | $32 |
| Kyowa Kirin, Inc. | 2 | $31 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Sanofi | 2 | $29 |
| Lilly USA, LLC | 2 | $28 |
| Aimmune Therapeutics, Inc. | 2 | $28 |
| Tandem Diabetes Care, Inc. | 1 | $26 |
| Philips North America LLC | 1 | $20 |
| Sobi, Inc | 1 | $17 |
| Insulet Corporation | 1 | $16 |
| Sandoz | 1 | $16 |
| Amphastar Pharmaceuticals, Inc. | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $15 |
| Mylan Institutional Inc. | 1 | $15 |
| Endo USA, Inc. | 1 | $14 |
| IBSA Pharma Inc. | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
| Rhythm Pharmaceuticals, Inc. | 1 | $14 |
| Albireo Pharma, Inc. | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
| Advanced Respiratory, Inc | 1 | $12 |
How this compares
$2,234 in reported general payments places this provider in the 95th percentile of 1,890 pediatrics providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 13 | $942,114 |
| ZenpepLipase/Protease/Amylase | 11 | $13,164 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $682 |
| Azithromycin | 11 | $255 |
| Famotidine | 13 | $11 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta | $140 | $942,11413 claims |
| Aimmune Therapeutics, Inc.Zenpep | $28 | $13,16411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,890 pediatrics providers in New Jersey.
Other pediatrics in West Orange
- Young ChaeEdison$523K
- Ronke DosunmuEast Orange$310K
- Steven MateretskyHackensack$290K
- Sara RaymondMorristown$288K
- Andrew MulbergCamden$264K
- Bram GreenbergLakewood$200K
- David ApelianBoonton$149K
- Rebecca FarberTenafly$135K
- Katerina HarwoodPaterson$91K
- Daniel RauchHackensack$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.